COVID-19 and Risk of Acute Ischemic Stroke and Acute Lung Injury in Patients With Type II Diabetes Mellitus: The Anti-inflammatory Role of Metformin
- PMID: 33718411
- PMCID: PMC7944640
- DOI: 10.3389/fmed.2021.644295
COVID-19 and Risk of Acute Ischemic Stroke and Acute Lung Injury in Patients With Type II Diabetes Mellitus: The Anti-inflammatory Role of Metformin
Abstract
Background: Coronavirus disease 19 (COVID-19) is regarded as an independent risk factor for acute ischemic stroke (AIS) due to the induction of endothelial dysfunction, coagulopathy, cytokine storm, and plaque instability. Method: In this retrospective cohort study, a total of 42 COVID-19 patients with type 2 diabetes mellitus (T2DM) who presented with AIS within 1 week of displaying COVID-19 symptoms were recruited. According to the current anti-DM pharmacotherapy, patients were divided into two groups: a Metformin group of T2DM patients with COVID-19 and AIS on metformin therapy (850 mg, 3 times daily (n = 22), and a Non-metformin group of T2DM patients with COVID-19 and AIS under another anti-DM pharmacotherapy like glibenclamide and pioglitazone (n = 20). Anthropometric, biochemical, and radiological data were evaluated. Results: Ferritin serum level was lower in metformin-treated patients compared to non-metformin treated patients (365.93 ± 17.41 vs. 475.92 ± 22.78 ng/mL, p = 0.0001). CRP, LDH, and D-dimer serum levels were also lowered in metformin-treated patients compared to non-metformin treated patients (p = 0.0001). In addition, lung CT scan scores of COVID-19 patients was 30.62 ± 10.64 for metformin and 36.31 ± 5.03 for non-metformin treated patients. Conclusion: Metformin therapy in T2DM patients was linked to a lower risk of AIS during COVID-19. Further studies are needed to observe the link between AIS in COVID-19 diabetic patients and metformin therapy.
Keywords: COVID-19; SARS-CoV-2; acute ischaemic stroke; diabates mellitus; metformin.
Copyright © 2021 Al-kuraishy, Al-Gareeb, Alblihed, Cruz-Martins and Batiha.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19.Pharmaceuticals (Basel). 2022 Nov 7;15(11):1361. doi: 10.3390/ph15111361. Pharmaceuticals (Basel). 2022. PMID: 36355535 Free PMC article.
-
The potential therapeutic effect of metformin in type 2 diabetic patients with severe COVID-19.Eur Rev Med Pharmacol Sci. 2023 Dec;27(23):11445-11456. doi: 10.26355/eurrev_202312_34583. Eur Rev Med Pharmacol Sci. 2023. PMID: 38095392
-
Investigating the impact of metformin on severity of COVID-19 in patients with Type 2 diabetes mellitus: Focusing on laboratory findings.Endocrinol Diabetes Metab. 2023 Sep;6(5):e441. doi: 10.1002/edm2.441. Epub 2023 Jul 11. Endocrinol Diabetes Metab. 2023. PMID: 37431844 Free PMC article.
-
Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): Boon or bane?Diabetes Metab Syndr. 2020 Sep-Oct;14(5):829-831. doi: 10.1016/j.dsx.2020.06.015. Epub 2020 Jun 10. Diabetes Metab Syndr. 2020. PMID: 32540737 Free PMC article. Review.
-
Stroke as a Potential Complication of COVID-19-Associated Coagulopathy: A Narrative and Systematic Review of the Literature.J Clin Med. 2020 Sep 28;9(10):3137. doi: 10.3390/jcm9103137. J Clin Med. 2020. PMID: 32998398 Free PMC article. Review.
Cited by
-
COVID-19 and corticosteroids: a narrative review.Inflammopharmacology. 2022 Aug;30(4):1189-1205. doi: 10.1007/s10787-022-00987-z. Epub 2022 May 13. Inflammopharmacology. 2022. PMID: 35562628 Free PMC article. Review.
-
SARS-CoV-2 infection and dysregulation of nuclear factor erythroid-2-related factor 2 (Nrf2) pathway.Cell Stress Chaperones. 2023 Nov;28(6):657-673. doi: 10.1007/s12192-023-01379-0. Epub 2023 Oct 5. Cell Stress Chaperones. 2023. PMID: 37796433 Free PMC article. Review.
-
Receptor for Advanced Glycation End Product, Organ Crosstalk, and Pathomechanism Targets for Comprehensive Molecular Therapeutics in Diabetic Ischemic Stroke.Biomolecules. 2022 Nov 18;12(11):1712. doi: 10.3390/biom12111712. Biomolecules. 2022. PMID: 36421725 Free PMC article. Review.
-
Receptor-dependent effects of sphingosine-1-phosphate (S1P) in COVID-19: the black side of the moon.Mol Cell Biochem. 2023 Oct;478(10):2271-2279. doi: 10.1007/s11010-023-04658-7. Epub 2023 Jan 18. Mol Cell Biochem. 2023. PMID: 36652045 Free PMC article.
-
Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.Front Immunol. 2021 Nov 11;12:749291. doi: 10.3389/fimmu.2021.749291. eCollection 2021. Front Immunol. 2021. PMID: 34867978 Free PMC article. Review.
References
-
- Al-Kuraishy HM, Al-Naimi MS, Lungnier CM, Al-Gareeb AI. Macrolides and COVID-19: an optimum premise. Biomed Biotechnol Res J. (2020) 4:189. 10.4103/bbrj.bbrj_103_20 - DOI
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous